SUMMARY In a patient with myasthenic syndrome neuro-muscular transmission was characterised by depression and facilitation. The relative extent of these two processes varied between muscles, and in the one muscle with time. Guanidine HCI treatment corrected the electrophysiological defect. Oral choline increased muscle action potential amplitude in response to single shocks. Intravenous choline produced features indicating cholinergic autonomic stimulation. Pimozide and plasmapheresis had no effect. Animal in-vivo and in-vitro studies performed to detect a circulating factor which interferes with neuro-muscular transmission were negative.
The myasthenic syndrome (MYS) is a well defined clinical entity.' There remain a number of unresolved aspeo**, including a lack of knowledge of the cause and mechanism of the disorder. We have quantified certain parameters of neuromuscular transmission in one patient with MYS in order to further define the pathophysiology of this condition. The transmission defect in MYS has two components, characterised by depression and facilitation. A variation in magnitude of these components with time, and at different neuro-muscular junctions, is demonstrated. This could explain the apparent concurrent presence of transmission features of myasthenia gravis (MG) and MYS which have been reported in scme patients. [2] [3] [4] The effect of certain pharmacological agents, in particular choline, was assessed, and the influence of plasmapheresis noted. The patient's serum was tested for its effect on n-euro-muscular transmission in animal in-vivo and in-vitro preparations.
Patients and methods
A 56 year old woman presented with several months history of proximal weakness. Thyroid function tests were in the toxic range: T3 7-5 nmol/I (1-0-2-7), T4 250 nmol/l (60-145), FTI 360 (50-140), T3 resin uptake 144% (80-110), 1311 thyroid uptake 20% at four hours. She was treated with carbimazole 60 mg/day and euthyroid status was reached after six weeks. Weakness persisted and three months later electrophysiological studies showed the characteristic features of MYS Guanidine HCI treatment resulted in a threefold increase in CAPa to 7-8 ±1 1 mV (mean + SD), range 6-7-9-2 mV. In association with this increase in CAPa, facilitation was no longer evident following exercise or during 20 Hz stimulation. An unexpected feature was noted after the first three days of guanidine treatment. The electrophysiological features of MYS were corrected in thenar muscles, but were still evident in the extensor digitorum brevis muscle ( fig 5) . After a further four days of treatment the defect was not apparent in either muscle group. The other drugs were administered when the patient was not receiving guanidine.
Edrophonium HCI infusion resulted in a 30% increase in CAPa. After one week of oral choline administration CAPa was 2-3 mV, and after a The application of quantitative analysis to the electrophysiological changes in MYS has two aims. It defines in more rigorous terms the transmission characteristics, and the way these fluctuate in time. It could be used to compare the nature and extent of the defect between patients. The other potential benefit is that an analysis of the transmission defect may provide a clue to its mechanism. This relates to physiological studies aimed at determining the processes which act to increase transmitter release during and following repetitive stimulation. These have been separated to an extent by their decay time constant. 10 Of the three processes arbitrarily subdivided on this criterion, our results fit the process of potentiation which decays with a time constant of tens of seconds to minutes. The variability in the decay constant shown in fig 4, also documents the fluctuation in transmission characteristics which occurs with time. The cause of this variability is uncertain. One possibility is that some change in the factor responsible for the pathophysiology of MYS is occurring. Another potential mechanism is change in local temperature. Animal studies have documented the sensitivity of facilitation of transmitter release to temperature, with the decay time constant of facilitation being inversely related to temperature." In MYS it has been found that cooling improves transmitter release'2 and similarly in MG transmission is better at lower temperatures. '3 The potentiating effect of edrophonium HCI has been noted previously. ' Acute choline administration appeared to have no effect on transmitter release at the neuromuscular junction. The clinical features exhibited by the patient were consistent with increased cholinergic autonomic activity. Transmission was therefore increased at some cholinergic sites. The mechanism underlying the difference in effect produced by acute and chronic choline administration, and in the acute setting the disparity in autonomic and neuro-muscular junction response remains uncertain. Animal studies indicate that the half-life of intravenously administered choline is less than one minute. The liver and kidneys remove 50%. Though conversion to ACh is rapid, it was concluded that this was a relatively minor pathway for choline metabolism.20 This coupled with the presence of specific high affinity transport systems for choline2' in parts of the nervous system suggests that in the acute setting available choline will be selectively distributed. The response to intravenous choline raises the possibility of acute manipulation of cholinergic function, in autonomic and possibly other parts of the nervous system. Plasmapheresis was without effect. If the MYS was related to the presence of a circulating antibody, as in MG, then the schedule of plasmapheresis used should have produced a beneficial effect. 22 If it was dependent _n a circulating factor other than an antibody improvement may still have been expected. Alternatively the postulated factor, as the polypeptide botulism toxin, could be tightly bound to its site of action and produce long lasting effects. This is supported by the finding that prolonged washing of 487 group.bmj.com on April 9, 2017 -Published by http://jnnp.bmj.com/ Downloaded from Henryk Kranz, David J Caddy, Andrew M Williams, and Wansoon Gay biopsied inter-costal muscle preparation from patients with MYS fails to alter the transmission block. 23 The lack of improvement in our patient over a long follow-up period argues against this possibility.
The animal and in-vitro studies showed no evidence to suggest the presence of a circulating factor which impairs neuro-muscular transmission. Fractionation or concentration of the serum was not performed, and it is possible that the methods used were too insensitive or in some other way inappropriate.
